Department of Anesthesiology, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan.
Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.
Asian J Anesthesiol. 2021 Dec 1;59(4):123-134. doi: 10.6859/aja.202112_59(4).0001. Epub 2021 Nov 19.
There have been immense advances in the safety and variety of intravenous anesthetic delivery systems including drug cost reduction, development of more effective opioids, and improvement in depth of anesthesia monitoring in the last 20 years. Propofol-based total intravenous anesthesia (TIVA) with target-controlled infusion (TCI) is relatively easy to practice. While this technique promotes a higher overall anesthesia quality and patient survival, especially for cancer patients, there are deficiencies in training and education of the technique. Therefore, the Society for Intravenous Anesthesia and the Association of Anesthetists (United Kingdom) have laid out guidelines in an attempt to highlight multiple important TIVA-related safety issues to help clinicians feel more confident. In the present article, we discuss five recommendations and four special clinical situations. Preparation, equipment familiarity, and safe delivery techniques are extremely important for the proper employment of this method. Herein, we emphasize the importance of proper education, and the clinical practice experience of the TIVA technique. Additionally, we suggest a modified connection method to set up a safely administered line. We highlight the advantages of using processed electroencephalogram monitoring (such as bispectral index or Entropy) to prevent awareness during TIVA administration in difficult clinical situations. These situations may include triple low patients (e.g., low blood pressure, low maintained effect-site concentration of propofol, and low body weight ≤ 18), obese patients, and patients with difficult infusion site monitoring or use of neuromuscular blocking agents. Due to a limited consensus among Taiwanese medical professionals, this document is intended to act as a safe practice reference for the use of TIVA with TCI. Additionally, two pithy formula codes, 4321 for propofol with fentanyl/alfentanil and 42222111 for propofol with remifentanil, are provided for the general population and one pithy formula code, 4321 for propofol with fentanyl, is provided for pediatric patients.
在过去的 20 年中,静脉麻醉输送系统在安全性和多样性方面取得了巨大进展,包括降低药物成本、开发更有效的阿片类药物以及改善麻醉深度监测。依托咪酯为基础的全静脉麻醉(TIVA)联合靶控输注(TCI)相对容易实施。虽然这种技术提高了整体麻醉质量和患者生存率,特别是对癌症患者,但在技术培训和教育方面存在不足。因此,静脉麻醉学会和麻醉医师协会(英国)制定了指南,试图强调与 TIVA 相关的多个重要安全问题,以帮助临床医生更有信心。在本文中,我们讨论了五个建议和四个特殊临床情况。准备、设备熟悉程度和安全输送技术对于正确使用这种方法非常重要。在这里,我们强调了适当教育的重要性以及 TIVA 技术的临床实践经验。此外,我们建议采用改良的连接方法来建立安全的给药线路。我们强调了在困难的临床情况下使用处理后的脑电图监测(如双频谱指数或熵)预防 TIVA 给药期间意识的重要性。这些情况可能包括三低患者(如低血压、低维持效应部位依托咪酯浓度和低体重≤18kg)、肥胖患者以及输注部位监测或使用神经肌肉阻滞剂困难的患者。由于台湾医疗专业人员之间存在有限的共识,本文件旨在为 TCI 下的 TIVA 使用提供安全实践参考。此外,还为一般人群提供了两个简洁的公式代码 4321(依托咪酯联合芬太尼/阿芬太尼)和 42222111(依托咪酯联合瑞芬太尼),为儿科患者提供了一个简洁的公式代码 4321(依托咪酯联合芬太尼)。